Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,934 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group C Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Pilot Study of Mothers and Babies Online in Home Visiting

NCT05714956
View directory record Official record
Conditions
Perinatal Depression
Interventions
Mothers and Babies Online (eMB)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Joliet, Illinois • Chariton, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

NCT01972529
View directory record Official record
Conditions
Thrombocytopenia Associated With Liver Disease
Interventions
avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
Lancaster, California • Long Beach, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 26, 2026, 5:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions
IDE196, Binimetinib, Crizotinib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 26, 2026, 5:45 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144

NCT07783308
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AZD4144
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Mesa, Arizona • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

NCT06178991
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
8,795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
106
States / cities
Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 26, 2026, 5:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

NCT00787176
View directory record Official record
Conditions
Pregnancy, Labor Pain
Interventions
Group A Intravenous bolus of 1000 ml lactated ringers solution, Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate, Group C 125 mL/hr of lactated ringers, Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

We The Village Family Support Study

NCT04250077
View directory record Official record
Conditions
Community Reinforcement And Family Training, Family Health, Substance-Related Disorders
Interventions
Community Reinforcement And Family Training (CRAFT), We The Village Peer Community Forum
Behavioral
Lead sponsor
We The Village, Inc.
Other
Eligibility
19 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sedentary Behavior Interrupted Randomized Controlled Trial (P2)

NCT03473145
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
Health Coaching, activPAL inclinometer, Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.
Behavioral · Device · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
55 Years and older · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 26, 2026, 5:45 AM EDT
Terminated Phase 3 Interventional Results available

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

NCT02455167
View directory record Official record
Conditions
Hepatitis C
Interventions
Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Mindfulness in Mood Dysregulated Youth

NCT02120937
View directory record Official record
Conditions
Bipolar Disorder, Mood Disorder, Emotional Disturbance
Interventions
MBCT-C Therapy
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining Dietary Pattern Accompanying Egg Intake Using Remote Food Photography Method

NCT03404700
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance
Interventions
Egg breakfast, Egg breakfast with high saturated fat, Cereal breakfast, Cereal breakfast with high saturated fat
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Exercise-based Motivational Interviewing for Fibromyalgia

NCT00573612
View directory record Official record
Conditions
Fibromyalgia
Interventions
Attention Control Counseling, Motivational Interviewing
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hearing for Communication and Resident Engagement

NCT04575051
View directory record Official record
Conditions
Hearing Loss, Age-Related
Interventions
Consult Model, Engage Model
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
684 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gingival Retraction for Digital Scan Data

NCT07119281
View directory record Official record
Conditions
Data Accuracy, Bleeding Control
Interventions
Group A: Cordless paste with astringent (EXP): Expasyl (Acteon PVT LTD), Group B: Cordless paste without astringent (MF): Magic FoamCord (Coltene Whaledent AG), Group C: Laser troughing (LT): Diode laser (iLase; Biolase Inc.), Group D: Retraction cord with astringent (RCA; Control group): Knitted cord impregnated with aluminum chloride (Ultrapak + Viscostat Clear; Ultradent Inc.)
Procedure
Lead sponsor
Istanbul University
Other
Eligibility
25 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 26, 2026, 5:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Myometrial Biopsy for the Detection of Infection

NCT00782665
View directory record Official record
Conditions
Infection
Interventions
Biopsy
Procedure
Lead sponsor
The Woman's Hospital of Texas
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2008 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

NCT00617994
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Fridley, Minnesota • Rochester, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 26, 2026, 5:45 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Characterization of Human Autoantibody Titers After Central Nervous System Insult

NCT03089749
View directory record Official record
Conditions
Brain Injuries, Traumatic, Spinal Cord Trauma, Intracranial Neoplasm
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 26, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

NCT03998514
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo
Drug
Lead sponsor
CohBar, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 26, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01005914
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, vincristine sulfate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 26, 2026, 5:45 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

NCT07652047
View directory record Official record
Conditions
Obesity & Overweight
Interventions
CX11, Placebo
Drug · Other
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 26, 2026, 5:45 AM EDT
Completed No phase listed Observational

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

NCT02580032
View directory record Official record
Conditions
Growth Disorder, Growth Hormone Deficiency in Children
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
4 Years to 13 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 26, 2026, 5:45 AM EDT